Company intelligence / Profile preview

iBody Inc.

Ownership: Private
Development stage: Clinical

Overview

iBody provides a unique antibody generation service using its proprietary Ecobody technology. This allows rapid production of high-affinity rabbit and human monoclonal antibodies suitable for challenging targets. The company supports both research reagent development and therapeutic antibody discovery for external partners.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodies (rabbit and human)Recombinant antibodiesDiagnostic and therapeutic antibodies
Industry: Drug Discovery Services

Drug pipeline

4 assets

WVE-006

IND Enabling

Indications: Alpha-1 antitrypsin deficiency

3 more assets in the full pipeline.

Request access →

Partnerships

No specific major pharma partnerships publicly disclosed. Collaborates with academic labs and industry clients on custom antibody generation.

Beyond the preview

Go deeper on iBody Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iBody Inc..

Explore the full profile